Altered cannabinoid receptor expression in pancreatic islets in experimental model of uraemia

• Autorzy: Nowinska P. , Niezgoda M. , Domian N. , Kasacka I.
• Języki publikacji: EN

Abstrakty

EN

Background: Uraemia leads to a number of metabolic and hormonal disorders including defective carbohydrate metabolism. Endocannabinoids exert their effect on insulin and glucagon secretion via activation of specific receptors named CB1 and CB2. For this reason and the absence of reports on location and immunoreactivity of CB1, CB2 receptors compared to immunoreactivity of insulin- and glucagon-secreting cells in experimental uraemia, the author decided to investigate this issue. The aim of the present study was the immunohistochemical localisation and evaluation of cannabinoid receptors (CB1, CB2), insulin and glucagon in the pancreatic islets of uraemic rats. Materials and methods: Fragments of the rat’s pancreas were collected 28 days after surgical resection of one kidney and removal of 70% of the other kidney cortex. Paraffin-embedded sections were stained with haematoxylin-eosin and immunohistochemical reactions were performed with the use of a specific antibody against CB1-, CB2-receptors, insulin and glucagon. Results: It was revealed the decreased immunoreactivity of the CB1 receptor and higher intensity of the immunohistochemical reaction against CB2 receptor as compared to the value in the control animals. Significantly higher immunoreactivity of glucagon-positive cells and weaker immunoreactivity of insulin-positive cells were observed in pancreatic islets of uraemic rats. Conclusions: The obtained results indicate the involvement of cannabinoid receptors in the pathomechanism of carbohydrate metabolism disorders, associated with abnormal secretion of hormones by the α and β cells in uraemia. (Folia Morphol 2020; 79, 3: 469–475)

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2020
• Tom: 79
• Numer: 3
• Opis fizyczny: p.469-475,fig.,ref.

Twórcy

autor

Nowinska P.

• Department of Histology and Cytophysiology, Medical University of Bialystok, Bialystok, Poland

autor

Niezgoda M.

• Department of Histology and Cytophysiology, Medical University of Bialystok, Bialystok, Poland

autor

Domian N.

• Department of Histology and Cytophysiology, Medical University of Bialystok, Bialystok, Poland

autor

Kasacka I.

• Department of Histology and Cytophysiology, Medical University of Bialystok, Bialystok, Poland

Bibliografia

• 1. Anderson RL, Randall MD, Chan SLF. The complex effects of cannabinoids on insulin secretion from rat isolated islets of Langerhans. Eur J Pharmacol. 2013; 706(1-3): 56–62, doi: 10.1016/j.ejphar.2013.02.034, indexed in Pubmed: 23499687.
• 2. Araki T, Ueda M, Ogawa K, et al. Histological pancreatitis in end-stage renal disease. Int J Pancreatol. 1992; 12(3): 263–269, doi: 10.1007/BF02924366, indexed in Pubmed: 1283864.
• 3. Baggenstoss AH. The pancreas in uremia; a histopathologic study. Am J Pathol. 1948; 24(5): 1003–1017, indexed in Pubmed: 18883950.
• 4. Bátkai S, Osei-Hyiaman D, Pan H, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 2007; 21(8): 1788–1800, doi: 10.1096/fj.06-7451com, indexed in Pubmed: 17327359.
• 5. Bermúdez-Siva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol. 2006; 531(1-3): 282–284, doi: 10.1016/j.ejphar.2005.12.016, indexed in Pubmed: 16423347.
• 6. Bermudez-Silva FJ, Sanchez-Vera I, Suárez J, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol. 2007; 565(1-3): 207–211, doi: 10.1016/j.ejphar.2007.02.066, indexed in Pubmed: 17499236.
• 7. Bermúdez-Silva FJ, Suárez J, Baixeras E, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia. 2008; 51(3): 476–487, doi: 10.1007/s00125-007-0890-y, indexed in Pubmed: 18092149.
• 8. Bilbrey GL, Faloona GR, White MG, et al. Hyperglucagonemia of renal failure. J Clin Invest. 1974; 53(3): 841–847, doi: 10.1172/JCI107624, indexed in Pubmed: 4812442.
• 9. DeFronzo RA, Andres R, Edgar P, et al. Carbohydrate metabolism in uremia: a review. Medicine (Baltimore). 1973; 52(5): 469–481, doi: 10.1097/00005792-197309000-00009, indexed in Pubmed: 4579981.
• 10. Després JP, Golay A, Sjöström L, et al. Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353(20): 2121–2134, doi: 10.1056/NEJMoa044537, indexed in Pubmed: 16291982.
• 11. Duvivier VF, Delafoy-Plasse L, Delion V, et al. Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats. Eur J Pharmacol. 2009; 616(1-3): 314–320, doi: 10.1016/j.ejphar.2009.05.024, indexed in Pubmed: 19482020.
• 12. Emmanouel DS, Lindheimer MD, Katz AI. Pathogenesis of endocrine abnormalities in uremia. Endocr Rev. 1980; 1(1): 28–44, doi: 10.1210/edrv-1-1-28, indexed in Pubmed: 6785085.
• 13. Getty-Kaushik L, Richard AMT, Deeney JT, et al. The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. Obesity (Silver Spring). 2009; 17(10): 1856–1860, doi: 10.1038/oby.2009.234, indexed in Pubmed: 19644453.
• 14. González-Mariscal I, Egan JM. Endocannabinoids in the Islets of Langerhans: the ugly, the bad, and the good facts. Am J Physiol Endocrinol Metab. 2018; 315(2): E174–E179, doi: 10.1152/ajpendo.00338.2017, indexed in Pubmed: 29631361.
• 15. Hager SR. Insulin resistance of uremia. Am J Kidney Dis. 1989; 14(4): 272–276, doi: 10.1016/s0272-6386(89)80201-x, indexed in Pubmed: 2679057.
• 16. Herman GE, Elfont EA. The taming of immunohistochemistry: the new era of quality control. Biotech Histochem. 1991; 66(4): 194–199, doi: 10.3109/10520299109109968, indexed in Pubmed: 1912080.
• 17. Janiak P, Poirier B, Bidouard JP, et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 2007; 72(11): 1345–1357, doi: 10.1038/sj.ki.5002540, indexed in Pubmed: 17882151.
• 18. Juan-Picó P, Fuentes E, Bermúdez-Silva FJ, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium. 2006; 39(2): 155–162, doi: 10.1016/j.ceca.2005.10.005, indexed in Pubmed: 16321437.
• 19. Kim W, Lao Q, Shin YK, et al. Cannabinoids induce pancreatic β-cell death by directly inhibiting insulin receptor activation. Sci Signal. 2012; 5(216): ra23, doi: 10.1126/scisignal.2002519, indexed in Pubmed: 22434934.
• 20. Koppe L, Nyam E, Vivot K, et al. Urea impairs β cell glycolysis and insulin secretion in chronic kidney disease. J Clin Invest. 2016; 126(9): 3598–3612, doi: 10.1172/JCI86181, indexed in Pubmed: 27525435.
• 21. Koppe L, Pelletier CC, Alix PM, et al. Insulin resistance in chronic kidney disease: new lessons from experimental models. Nephrol Dial Transplant. 2014; 29(9): 1666–1674, doi: 10.1093/ndt/gft435, indexed in Pubmed: 24286973.
• 22. Laychock SG, Hoffman JM, Meisel E, et al. Pancreatic islet arachidonic acid turnover and metabolism and insulin release in response to delta-9-tetrahydrocannabinol. Biochem Pharmacol. 1986; 35(12): 2003–2008, doi: 10.1016/0006-2952(86)90733-1, indexed in Pubmed: 3013206.
• 23. Li C, Jones PM, Persaud SJ. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther. 2011; 129(3): 307–320, doi: 10.1016/j.pharmthera.2010.10.006, indexed in Pubmed: 21055418.
• 24. Lin CY, Hsu YJ, Hsu SC, et al. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia. J Mol Cell Cardiol. 2015; 85: 249–261, doi: 10.1016/j.yjmcc.2015.06.010, indexed in Pubmed: 26093151.
• 25. Malenczyk K, Keimpema E, Piscitelli F, et al. Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture. Proc Natl Acad Sci U S A. 2015; 112(45): E6185–E6194, doi: 10.1073/pnas.1519040112, indexed in Pubmed: 26494286.
• 26. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006; 91(8): 3171–3180, doi: 10.1210/jc.2005-2679, indexed in Pubmed: 16684820.
• 27. Montecucco F, Lenglet S, Braunersreuther V, et al. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol. 2009; 46(5): 612–620, doi: 10.1016/j.yjmcc.2008.12.014, indexed in Pubmed: 19162037.
• 28. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept. 2008; 145(1-3): 49–53, doi: 10.1016/j.regpep.2007.08.009, indexed in Pubmed: 17884194.
• 29. Neirynck N, Vanholder R, Schepers E, et al. An update on uremic toxins. Int Urol Nephrol. 2013; 45(1): 139–150, doi: 10.1007/s11255-012-0258-1, indexed in Pubmed: 22893494.
• 30. Polak A, Harasim E, Chabowski A. Effects of activation of endocannabinoid system on myocardial metabolism. Postepy Hig Med Dosw (Online). 2016; 70(0): 542–555, doi: 10.5604/17322693.1202483, indexed in Pubmed: 27333924.
• 31. Sherwin RS, Bastl C, Finkelstein FO, et al. Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. J Clin Invest. 1976; 57(3): 722–731, doi: 10.1172/JCI108330, indexed in Pubmed: 1249205.
• 32. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013; 17(4): 475–490, doi: 10.1016/j.cmet.2013.03.001, indexed in Pubmed: 23562074.
• 33. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63(5): 1934–1943, doi: 10.1046/j.1523-1755.2003.00924.x, indexed in Pubmed: 12675874.
• 34. Vilches-Flores A, Delgado-Buenrostro NL, Navarrete-Vázquez G, et al. CB1 cannabinoid receptor expression is regulated by glucose and feeding in rat pancreatic islets. Regul Pept. 2010; 163(1-3): 81–87, doi: 10.1016/j.regpep.2010.04.013, indexed in Pubmed: 20451564.
• 35. Wang PF, Jiang LS, Bu J, et al. Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury. J Cardiovasc Pharmacol. 2012; 59(4): 301–307, doi: 10.1097/FJC.0b013e3182418997, indexed in Pubmed: 22113346.
• 36. Xu H, Carrero JJ. Insulin resistance in chronic kidney disease. Nephrology (Carlton). 2017; 22 Suppl 4: 31–34, doi: 10.1111/nep.13147, indexed in Pubmed: 29155496.

Identyfikatory

DOI

10.5603/FM.a2019.0114